6533b833fe1ef96bd129c9d0

RESEARCH PRODUCT

Ovarian Cancer: Primary Advanced and Recurrent Disease

Ilaria SabatucciGiuseppa MalteseDomenica LorussoLorena IncorvaiaStefano Lepori

subject

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentTreatment optionsDiseasemedicine.diseaseSystemic therapyInternal medicinemedicineRecurrent diseaseEpithelial ovarian cancerStage (cooking)businessOvarian cancer

description

Approximately 70% of patients affected by epithelial ovarian cancer (EOC) are diagnosed with FIGO stage III–IV disease and 50–70% of them will develop a recurrence, after a median progression-free survival (PFS) of approximately 18 months. The 5-year survival for stage III and IV ranges from 39% to 17%, respectively. Treatment options for primary advanced and recurrent disease comprehend surgery (primary cytoreductive surgery or interval cytoreductive surgery after neoadjuvant chemotherapy for primary advanced disease and secondary cytoreductive surgery for recurrent disease) and systemic therapy (standard and novel chemotherapeutic agents and biological agents).

yearjournalcountryeditionlanguage
2021-01-01
https://doi.org/10.1007/978-3-030-56051-5_52